The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Iberdomide is the first in a new class of medicines called cereblon E3 ligase modulator (CELMoD) agents, which utilize targeted protein degradation to reach proteins previously considered undruggable.
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a complete response rate of 44 percent. A global phase 3 trial is currently recruiting patients to serve as a confirmatory study for the indication.
In a phase 3 clinical trial, the combination showed significant improvements in progression-free survival and overall survival compared with the standard of care.
In five years, we hope to have a national system for prescreening to determine eligibility for experimental cancer medicine, allowing the UK to give patients access to trials faster than anywhere else in the world.
Results from the phase 3 VERIFY study supported the filing, showing that the drug improved hematocrit levels and lowered the frequency of required blood removals.
To access the SOHO Career Center click the following link.
